Carmot Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing therapeutics for obesity and diabetes. In early 2024 the company was acquired by Roche, becoming part of the Roche Group. The company leverages a chemotype evolution platform to discover novel incretin receptor signaling targets, advancing a pipeline of potential treatments for metabolic disease.
Carmot Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Clinical-stage, Obesity, and Diabetes.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: carmot-therapeutics
name: Carmot Therapeutics
description: Carmot Therapeutics, Inc. is a clinical‑stage biotechnology company focused on developing therapeutics for obesity
and diabetes. In early 2024 the company was acquired by Roche, becoming part of the Roche Group. The company leverages a
chemotype evolution platform to discover novel incretin receptor signaling targets, advancing a pipeline of potential treatments
for metabolic disease.
url: https://raw.githubusercontent.com/api-evangelist/carmot-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment pass 2026-10-07 (modular-v1; was harvest)
specificationVersion: '0.20'
created: '2026-10-07'
modified: '2026-10-07'
tags:
- Company
- Biotechnology
- Clinical-stage
- Obesity
- Diabetes
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Hosts
url: hosts/carmot-therapeutics-hosts.yml
- type: Vendors
url: vendors/carmot-therapeutics-vendors.yml
- type: DomainSecurity
url: security/carmot-therapeutics-domain-security.yml
- type: Website
url: https://forgeglobal.com/carmot-therapeutics_stock/
apis: []
x-coverage:
state: blocked
reason: bot-challenge
method: derived
generated: '2026-10-07'
generator: derive-coverage.py (pre-flight evidence)
detail: the company's own front door answers a browser with an anti-bot challenge, so nothing behind it is reachable by
any reader
evidence:
- url: https://forgeglobal.com/carmot-therapeutics_stock/
status: 403
x-enrichment:
date: '2026-10-07'
status: enriched
artifacts_added: 3
pass: modular-v1
engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →